Search Results - "ASONG, MARISSE"

FLT3 Is Sumoylated and Localizes to the Nucleus in Acute Myeloid Leukemia by Asong, Marisse, Kazi, Julhash Uddin, Ronnstrand, Lars

“…FLT3 is a receptor tyrosine kinase (RTK) that is mutated and constitutively active in 30% of patients with acute myeloid leukemia (AML). Notably, mutations in…”
Get full text

Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial by Lingvay, Ildiko, Asong, Marisse, Desouza, Cyrus, Gourdy, Pierre, Kar, Soumitra, Vianna, André, Vilsbøll, Tina, Vinther, Siri, Mu, Yiming

“…IMPORTANCE: Once-weekly insulin icodec could provide a simpler dosing alternative to daily basal insulin in people with type 2 diabetes. OBJECTIVE: To evaluate…”
Get full text

Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial by Philis-Tsimikas, Athena, Asong, Marisse, Franek, Edward, Jia, Ting, Rosenstock, Julio, Stachlewska, Karolina, Watada, Hirotaka, Kellerer, Monika

“…Insulin icodec (icodec) is a once-weekly basal insulin currently under development. ONWARDS 2 aimed to assess the efficacy and safety of once-weekly icodec…”
Get full text

824-P: No Evidence of Increased Physical Activity–Related Hypoglycemia with Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 1 Diabetes-ONWARDS 6 by Sourij, Harald, Bracken, Richard M, Asong, Marisse, Carstensen, Lisbeth, Watt, Sara K, Philis-Tsimikas, Athena

“…Introduction & Objective: ONWARDS 6 compared the efficacy and safety of once-weekly insulin icodec (icodec) and once-daily insulin degludec (degludec) in…”
Get full text

830-P: No Evidence of Increased Physical Activity–Related Hypoglycemia with Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes-ONWARDS 1–5 by Riddell, Michael C, Heller, Simon R, Asong, Marisse, Carstensen, Lisbeth, Watt, Sara K, Woo, Vincent C

“…Introduction & Objective: The ONWARDS (ON) phase 3a trials showed the efficacy and safety of once-weekly (OW) basal insulin icodec (icodec) vs once-daily (OD)…”
Get full text

178-OR: Better Glycemic Control with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Degludec in Insulin-Naïve Type 2 Diabetes (ONWARDS 3) by LINGVAY, ILDIKO, ASONG, MARISSE, DESOUZA, CYRUS, GOURDY, PIERRE, KAR, SOUMITRA, VIANNA, ANDRE G., VILSBØLL, TINA, VINTHER, SIRI M., MU, YIMING

“…Efficacy and safety of once-weekly insulin icodec (icodec) vs once-daily insulin degludec (degludec) in insulin-naïve adults with T2D were examined in ONWARDS…”
Get full text

191-OR: Similar Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin Naïve or Experienced Patients with T2D by SILVER, ROBERT J., ASONG, MARISSE, BEGTRUP, KAMILLA, KOEFOED, METTE M., HELLER, SIMON R., ROSENSTOCK, JULIO

“…Insulin icodec* (icodec) is a novel once-weekly basal insulin analog in development. This post hoc analysis explored hypoglycemia duration using double-blinded…”
Get full text

Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes by Pieber, Thomas R., Asong, Marisse, Fluhr, Gabriele, Höller, Vera, Kristensen, Niels R., Larsen, Jonas H., Ribel‐Madsen, Rasmus, Svehlikova, Eva, Vinther, Siri, Voortman, Margarete, Haahr, Hanne

“…Abstract Aims To characterize the pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in type 2 diabetes (T2D). Materials and Methods…”
Get full text

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D by Manjunath, Aparna, Silver, Robert J, Asong, Marisse, Begtrup, Kamilla, Koefoed, Mette M, Heller, Simon R, Rosenstock, Julio

“…Insulin icodec* (icodec) is a novel once-weekly basal insulin analog in development. This post hoc analysis explored hypoglycemia duration using double-blinded…”
Get full text

Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain by Robador, Jose R, Feinauer, Manuel J, Schneider, Stefan W, Mayer, Frank T, Gorzelanny, Christian, Sacharow, Artur, Liu, Xiaobo, Berghoff, Anna, Brehm, Maria A, Hirsch, Daniela, Stadler, Julia, Vidal-Y-Si, Sabine, Wladykowski, Ewa, Asong, Marisse, Nowak, Kai, Seiz-Rosenhagen, Marcel, Umansky, Viktor, Mess, Christian, Pantel, Klaus, Winkler, Frank, Bauer, Alexander T

“…The prognosis of patients with brain metastases (BM) is poor despite advances in our understanding of the underlying pathophysiology. The high incidence of…”
Get full text